Literature DB >> 11196547

Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis.

J F Viallard1, J L Taupin, V Ranchin, B Leng, J L Pellegrin, J F Moreau.   

Abstract

OBJECTIVE: Eosinophilic fasciitis (EF) is a scleroderma-like disease of unknown etiology characterized by skin induration, elevated immune globulins, and peripheral eosinophilia. The hallmarks of the chronic cutaneous involvement in this syndrome are inflammation and fibrosis of the fascia. To determine how the inflammatory process in EF may be regulated, we investigated the spontaneous and mitogen induced [lipopolysaccharide (LPS), phytohemagglutinin (PHA) or both LPS+PHA] syntheses of interleukins (IL)-2, 5 and 10, interferon-gamma (IFN-gamma), and leukemia inhibitory factor (LIF) cytokines by peripheral blood mononuclear cells (PBMC) from 4 patients with active EF and compared them to those of 10 healthy individuals.
METHODS: We used a short term whole blood assay and culture supernatants were collected after 24 h to measure the IL-2 and IFN-gamma contents and after 48 h to evaluate IL-5, IL-10, and LIF. Supernatant cytokine concentrations were determined by ELISA.
RESULTS: All 4 patients had similar patterns of cytokine secretion. Cytokine production did not differ between patients and controls under basal conditions or when LPS was added to the cultures. In contrast, under PHA or LPS+PHA stimulation, significantly higher amounts of all 5 cytokines were detected in samples from patients compared to those from controls.
CONCLUSION: Overall, our data suggest that EF is characterized by an increased capacity of PBMC to produce IL-5 and IL-10, possibly leading to eosinophilia and immune globulin overexpression. In this context, the simultaneous elevations of type 1 cytokines (IL-2 and IFN-gamma) and LIF production by the same cells may be an attempt by the immune system to limit the exacerbation of a type 2 dominant response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196547

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.

Authors:  Dagmar Simon; Andrew Wardlaw; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

2.  Eosinophilic fasciitis induced by fire ant bites.

Authors:  Jyothi R Mallepalli; Robert J Quinet; Rachana Sus
Journal:  Ochsner J       Date:  2008

Review 3.  Scleroderma-like cutaneous syndromes.

Authors:  Yasuji Mori; Veli-Matti Kahari; John Varga
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

4.  Atypical Presentation of Eosinophilic Fasciitis with Pitting Edema.

Authors:  Chih-Wei Chang; Matthew S Lau
Journal:  Hawaii J Med Public Health       Date:  2015-09

Review 5.  The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.

Authors:  Francisco Vílchez-Oya; Julia María Sánchez-Schmidt; Anna Agustí; Ana Pros
Journal:  Clin Rheumatol       Date:  2020-01-23       Impact factor: 2.980

Review 6.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

7.  Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.

Authors:  Sa Rang Kim; Alexandra Charos; William Damsky; Peter Heald; Michael Girardi; Brett A King
Journal:  JAAD Case Rep       Date:  2018-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.